scispace - formally typeset
Search or ask a question
Author

V. B. Grinevich

Bio: V. B. Grinevich is an academic researcher from Military Medical Academy. The author has contributed to research in topics: Coronavirus & Steatohepatitis. The author has an hindex of 1, co-authored 3 publications receiving 6 citations.

Papers
More filters
Journal ArticleDOI
22 May 2021
TL;DR: The presented clinical practice guidelines of the Gastroenterological Scientific Society of Russia (GSSR), diagnostic, and therapeutic approaches for patients with digestive diseases during the COVID-19 pandemic were approved by the XXIII Congress of the GSSR and the 22nd International Slavonic-Baltic Scienti fi c Forum “St. Petersburg - Gastro-2020 ON-LINE”.
Abstract: The presented clinical practice guidelines of the Gastroenterological Scientific Society of Russia (GSSR), diagnostic, and therapeutic approaches for patients with digestive diseases during the COVID-19 pandemic. The guidelines were approved by the XXIII Congress of the GSSR and the 22nd International Slavonic-Baltic Scientifi c Forum “St. Petersburg - Gastro-2020 ON-LINE” (St. Petersburg, June 11, 2020). The presented clinical practice guidelines of the Russian Scientific Medical Society of Internal Medicine (RSMSIM) and the Gastroenterological Scientific Society of Russia (GSSR), diagnostic, and therapeutic approaches for patients with digestive diseases during the COVID-19 pandemic. The recommendations were approved at the XV National Congress of Internal Medicine, XXIII Congress of NOGR on the basis of the 1st edition, adopted at the 22nd International Slavic- Baltic Scientific Forum “St. Petersburg - Gastro-2020 ON-LINE”.

8 citations

Journal ArticleDOI
07 Apr 2021
TL;DR: The article presents the results of the analysis of clinical features of gastroenterological manifestations of a new coronavirus infection (COVID-19) caused by the pathogen SARS-CoV-2, carried out in accordance with Temporary guidelines of the Ministry of health of the Russian Federation.
Abstract: The article presents the results of the analysis of clinical features of gastroenterological manifestations of a new coronavirus infection (COVID-19) caused by the pathogen SARS-CoV-2 Taking into account the stage-by-stage system assessment of the experience of treating 1,180 patients in a multi-specialty hospital transformed into an infectious hospital, the most characteristic clinical manifestations of digestive damage by SARS-CoV-2 coronavirus are described The article focuses on verification of changes in the digestive system, both at the stage of primary examination, and during etiotropic (in combination with hydroxychloroquine and azithromycin, interferon-alpha drugs), pathogenetic (in combination with corticosteroids, heparin drugs, according to indications - an interleukin-6 inhibitor) and symptomatic (antipyretics, antiemetics and antitussive drugs) therapy, carried out in accordance with Temporary guidelines of the Ministry of health of the Russian Federation “Prevention, diagnosis and treatment of new coronavirus infection Covid-19” Directions for the development of algorithms for clinical and laboratory, instrumental and radiological diagnostics of changes in the digestive system in patients with COVID-19 are justified

2 citations


Cited by
More filters
Journal Article
TL;DR: The results of this case series suggest that high-dose oral famotidine is well tolerated and associated with improved patient-reported outcomes in non-hospitalised patients with COVID-19.
Abstract: Objective: Treatment options for nonhospitalized patients with coronavirus disease 2019 (COVID-19) to reducemorbidity, mortality, and spread of the disease are an urgent global need The over-the-counter histamine-2 receptorantagonist famotidine is a putative therapy for COVID-19 We quantitively assessed longitudinal changes in patient-reported outcome measures in nonhospitalized patients with COVID-19 who self-administered high-dose famotidineorally Design: Patients were enrolled consecutively after signing written informed consent Data on demographics, COVID-19 diagnosis, famotidine use, drug related side-effects, temperature measurements, oxygen saturations, and symptom scores were obtained using questionnaires and telephone interviews Based on an NIH-endorsedProtocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms(cough, shortness of breath, fatigue, headaches, and anosmia) and general unwellness on a 4-point ordinal scalemodeled on performance status scoring All data are reported at the patient level Longitudinal combined normalizedsymptom scores were statistically compared Results: Ten consecutive patients with COVID-19 who self-administered high-dose oral famotidine were identified The most frequently used famotidine regimen was 80mg three times daily (n=6) for a median of 11 days (range: 5 to21 days) Famotidine was well tolerated All patients reported marked improvements of disease-related symptomsafter starting famotidine The combined symptom score improved significantly within 24 hours of starting famotidineand peripheral oxygen saturation (n=2), and device recorded activity (n=1) increased Conclusions: The results of this case series suggest that high-dose oral famotidine is well tolerated and associated with improved patient reported outcomes in nonhospitalized patients with COVID-19 A blinded outpatient trial isplanned The findings may be transferable and relevant to the treatment of patients with cancer and COVID-19

27 citations

01 Jan 2010
TL;DR: Research of the etiological structure of acute hepatitis of unknown origin has allowed verifying the hepatitis E at 5,6% cases, DNA EBV was found out at 2,8% cases and 2,4% of patients had RNA HGV in blood.
Abstract: Research of the etiological structure of acute hepatitis of unknown origin has allowed verifying the hepatitis E at 5,6% cases, DNA EBV was found out at 2,8% cases and 2,8% of patients had RNA HGV in blood. The data of the anamnesis and a clinical and laboratory picture does not allow excluding at 31% of patients a drug-induced liver injury.

11 citations

Journal ArticleDOI
23 Jun 2020
TL;DR: The mechanisms of gastrointestinal tract (gastrointestinal tract) invasion by coronavirus SARSCoV-2 are described — induction of inflamation and violation of the permeability of the gastrointestinal mucosa, changes in the composition and function of the intestinal microbiota, impaired intestinal-lung axis interaction.
Abstract: Frequent damage to the digestive system with a new coronavirus infection, as well as its combination with gastroenterological pathology complicates the whole complex of therapeutic and diagnostic measures for such patients Understanding the problem is complicated by a large number of conflicting scientifi c data of varying degrees of evidence The article describes the mechanisms of gastrointestinal tract (gastrointestinal tract) aff ection by coronavirus SARSCoV-2 — induction of infl ammation and violation of the permeability of the gastrointestinal mucosa, changes in the composition and function of the intestinal microbiota, impaired intestinal-lung axis interaction features of the clinical picture aff ecting the prognosis of the disease, explains the features of the examination, and suggests treatment methods The article shows the features of the clinical picture that aff ect the prognosis of the disease, explains the features of the examination, suggests methods of treatment and nutritional support

10 citations

Journal ArticleDOI
14 Aug 2021
TL;DR: Therapy for patients with COVID-19 should include therapeutic approaches aimed at correcting disorders of the intestinal microbiota, intestinal barrier permeability, and relief of gastroenterological manifestations.
Abstract: With a new coronavirus infection (COVID-19), gastroenterological symptoms are often detected, which is due to both the damage to the digestive organs by the SARS-CoV-2 coronavirus and the exacerbation of chronic diseases, as well as aggressive multicomponent therapy. The severity of gastroenterological manifestations, primarily impaired liver function, is associated with a more severe and complicated course of COVID-19 infection. Numerous mechanisms of damage to the digestive organs in COVID-19 have been identified: direct damage by the virus due to resuscitation and multicomponent therapy, impaired central and peripheral nervous regulation, immunothrombotic syndrome, virus persistence in the gastrointestinal tract, induction of autoimmune reactions by the virus, humoral disorders (changes in serotonin levels, bradykinin, activation of mast cells). Violation of the microbial-tissue complex of the intestine and the permeability of the intestinal barrier, induced by the SARS-CoV-2 virus, ensures the formation and progression of chronic systemic inflammation, cytokine aggression, insulin resistance, endothelial dysfunction, which affect the severity of the infection. Therapy for patients with COVID-19 should include therapeutic approaches aimed at correcting disorders of the intestinal microbiota, intestinal barrier permeability, and relief of gastroenterological manifestations

3 citations

Journal ArticleDOI
02 Sep 2021
TL;DR: Treatment of patients with diffuse liver diseases includes lifestyle and nutritional modification, the use of hepatoprotective drugs, and means of correcting the intestinal barrier.
Abstract: Liver dysfunction is common with COVID-19 infection, and the prevalence is higher in men as well as in the elderly. Manifestations of liver damage such as high aspartate aminotransferase and alanine aminotransferase activity, increased bilirubin levels, low albumin levels, and prolonged prothrombin time are associated with severe COVID-19 infection. Mortality in patients with diffuse liver diseases without cirrhosis with COVID-19 infection was 12 %, in the presence of liver cirrhosis up to 40%, decompensated liver cirrhosis up to 4363%. The mechanisms of liver damage in COVID-19 include direct hepatotoxicity and indirect liver damage (due to systemic inflammation with impaired immunity, sepsis, hypoxia, ischemia, coagulopathy, endotheliitis, right ventricular failure, worsening of the course of existing liver diseases, drug liver damage). Treatment of patients with diffuse liver diseases includes lifestyle and nutritional modification, the use of hepatoprotective drugs, and means of correcting the intestinal barrier (bibliography: 30 refs).

2 citations